1. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations 
Raymond G. Slavin, MD, Caterina Ferioli, BSc, Stacey J. Tannenbaum, PhD, Carmen Martin, PhD, Martin Blogg, BSc, Philip J. Lowe, PhD 
Journal of Allergy and Clinical Immunology 
Volume 123, Issue 1, Pages e3 (January 2009)
DOI: /j.jaci
Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Example fits of the model for a single 300-mg dose (A) and multiple 4-weekly 150-mg doses (B) to samples collected from 2 individual patients showing model fits for each patient's plasma omalizumab, total IgE, and free IgE. Individual patient predictions for free IgE in all omalizumab-treated patients from the INNOVATE study (C).
Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci )
Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig 2
Symptom scores (A), PEF (B), and rescue medication use (C) in the overall omalizumab-treated population compared with placebo. The black bar above each plot designates the treatment duration. Model-predicted omalizumab concentrations (D) and free IgE concentrations (E) are also shown.
Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci )
Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Fig 3
Symptom scores (A), PEF (B), rescue medication use (C), model-predicted omalizumab concentrations (D), and model-predicted free IgE concentrations (E) in response to omalizumab in physician-evaluated responders and nonresponders.
Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci )
Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5. Fig 4
The change from the baseline (time zero) value of the total symptom score, morning PEF (L/min), and rescue medication use (puffs) correlate with free IgE (A) and omalizumab (B) concentrations in the overall omalizumab-treated population. To allow comparison across many different dosing levels, omalizumab is expressed as a percentage of each individual patient's steady-state average concentration.
Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci )
Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6. Fig 5
Correlation between levels of free IgE (A) and omalizumab (B) and clinical outcomes in responders (circles) and nonresponders (crosses) while on treatment and after cessation of omalizumab therapy. To allow comparison across many different dosing levels, omalizumab is expressed as a percentage of each individual patient's steady-state average concentration.
Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci )
Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7. Correlation between levels of free IgE and omalizumab and clinical outcomes in responders (circles) and nonresponders (crosses) while on treatment and after cessation of omalizumab therapy, including data from placebo-treated patients. To allow comparison across many different dosing levels, omalizumab is expressed as a percentage of each individual patient's steady-state average concentration.
Journal of Allergy and Clinical Immunology  , e3DOI: ( /j.jaci )
Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions